<DOC>
	<DOCNO>NCT00619099</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety two different dose schedule DACOGEN® ( decitabine ) Injection patient Myelodysplastic Syndromes ( MDS ) .</brief_summary>
	<brief_title>A Study Decitabine Given Subcutaneously Adults With Low Intermediate-1 Risk Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description>This randomize open-label Phase 2 efficacy safety study two ( 2 ) subcutaneous ( SQ ) dose schedule decitabine subject Low Intermediate 1 Risk MDS . This study conduct 6 study center United States . The primary efficacy outcome overall improvement rate . These two dos administer subcutaneously . The probability one schedule superior estimate , level toxicity schedule also evaluate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Each patient must meet follow criterion enrol study : 1 . Male female patient age 18 year old . 2 . Patients must sign institutional review board ( IRB ) approve informed consent form , understand investigational nature study potential hazard prior initiation studyspecific procedure treatment . 3 . Must Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 4 . Adequate renal hepatic function ( creatinine &lt; 2 time upper limit normal , total bilirubin &lt; 2 time upper limit normal , AST ALT ≤ 2 time upper limit normal ) unless proven related disease infiltration . 5 . Female patient need negative serum urine pregnancy test within 7 day prior study drug administration ( applies patient childbearing potential . Nonchildbearing define ≥ 1 year postmenopausal surgically sterilize ) . 6 . Women childbearing potential men must use contraception . Men woman must continue birth control duration study . 7 . Patients Low Intermediate1 Risk MDS International Prognostic Scoring System ( IPSS ) classification . Patients meet follow criterion exclude study : 1 . Women pregnant nursing . 2 . Those received prior therapy decitabine . 3 . Prior therapy azacitidine ( Vidaza® ) . 4 . Those received growth factor support lenalidomide 30 day prior first dose decitabine . 5 . Those received investigational agent 30 day prior first dose decitabine . 6 . Patients active , uncontrolled , systemic infection consider opportunistic , life threaten clinically significant ; severe , concurrent disease , , judgment Investigator discussion Sponsor Primary Investigator , would make patient inappropriate study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>MGI PHARMA , Inc .</keyword>
</DOC>